DK1082338T3 - 17-beta-nitro-11-beta-arylsteroider og derivater heraf med hormonale agonist- eller antagonistegenskaber - Google Patents

17-beta-nitro-11-beta-arylsteroider og derivater heraf med hormonale agonist- eller antagonistegenskaber

Info

Publication number
DK1082338T3
DK1082338T3 DK99924208T DK99924208T DK1082338T3 DK 1082338 T3 DK1082338 T3 DK 1082338T3 DK 99924208 T DK99924208 T DK 99924208T DK 99924208 T DK99924208 T DK 99924208T DK 1082338 T3 DK1082338 T3 DK 1082338T3
Authority
DK
Denmark
Prior art keywords
beta
nitro
derivatives
antagonist properties
hormonal agonist
Prior art date
Application number
DK99924208T
Other languages
Danish (da)
English (en)
Inventor
John A Kepler
Rupa S Shetty
C Edgar Cook
David Yue-Wei Lee
Gary S Bartley
Original Assignee
Res Triangle Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Triangle Inst filed Critical Res Triangle Inst
Application granted granted Critical
Publication of DK1082338T3 publication Critical patent/DK1082338T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99924208T 1998-05-29 1999-05-28 17-beta-nitro-11-beta-arylsteroider og derivater heraf med hormonale agonist- eller antagonistegenskaber DK1082338T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/086,674 US5962444A (en) 1998-05-29 1998-05-29 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties

Publications (1)

Publication Number Publication Date
DK1082338T3 true DK1082338T3 (da) 2006-11-20

Family

ID=22200129

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99924208T DK1082338T3 (da) 1998-05-29 1999-05-28 17-beta-nitro-11-beta-arylsteroider og derivater heraf med hormonale agonist- eller antagonistegenskaber

Country Status (12)

Country Link
US (3) US5962444A (es)
EP (1) EP1082338B1 (es)
JP (1) JP4545930B2 (es)
AT (1) ATE334139T1 (es)
AU (1) AU753355B2 (es)
CA (1) CA2333668C (es)
CY (1) CY1106444T1 (es)
DE (1) DE69932515T2 (es)
DK (1) DK1082338T3 (es)
ES (1) ES2270597T3 (es)
PT (1) PT1082338E (es)
WO (1) WO1999062929A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20030207854A1 (en) * 2001-03-23 2003-11-06 Simons, Jr. S. Stoney Antiprogestins with partial agonist activity
FR2842108B1 (fr) * 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
AU2008265898B2 (en) * 2007-06-15 2013-11-28 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
MX2017005163A (es) 2014-11-17 2018-01-18 Arno Therapeutics Inc Composiciones de liberación prolongada de onapristona y métodos.
CA2998924A1 (en) * 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
MX2018007154A (es) 2015-12-15 2019-01-10 Context Biopharma Inc Composiciones de onapristona amorfa y metodos para hacer las mismas.
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE287510C (es) *
DE290198C (es) *
DE289539C (es) *
US3187022A (en) * 1964-01-31 1965-06-01 Parke Davis & Co 17beta-amino-17alpha-pregnen-20-one compounds and the production thereof
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
EP0116974B1 (de) * 1983-02-18 1986-10-29 Schering Aktiengesellschaft 11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3306121A1 (de) * 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-spirolaktone in der steroidreihe, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische praeparate
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
NZ214998A (en) * 1985-02-07 1989-06-28 Schering Ag 13-(methyl or ethyl)-11-beta-phenyl-gonane derivatives; preparatory processes and pharmaceutical compositions
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4861763A (en) * 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
DE3702383A1 (de) * 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
FR2610933B1 (fr) * 1987-02-18 1989-06-09 Roussel Uclaf Nouveaux 19-nor steroides substitues en position 7, leur preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
ATE69820T1 (de) * 1987-04-24 1991-12-15 Akzo Nv 11-arylestranderivate und 11-arylpregnanderivate.
FR2618783B1 (fr) * 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
EP0321010B1 (en) * 1987-12-12 1993-02-03 Akzo N.V. New 11-arylsteroid compounds
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
SG44766A1 (en) * 1989-06-20 1997-12-19 Philips Electronics Nv Transmission output reducing signal processing device
EP0411733B1 (de) * 1989-08-04 1998-10-21 Schering Aktiengesellschaft 11 Beta-Aryl-gona-4,9-dien-3-one
DE4042005A1 (de) * 1990-12-22 1992-06-25 Schering Ag D-homo-(16-en)-11(beta)-aryl-4-estrene
ZA929315B (en) * 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
WO1993021926A1 (en) * 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
PT900234E (pt) * 1996-05-01 2000-12-29 Us Gov Health & Human Serv Derivados de progesterona substituidos em 21 que podem ser utilizados como novos agentes antiprogestativos
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties

Also Published As

Publication number Publication date
EP1082338A4 (en) 2004-12-29
ES2270597T3 (es) 2007-04-01
CY1106444T1 (el) 2011-10-12
CA2333668A1 (en) 1999-12-09
WO1999062929A1 (en) 1999-12-09
AU753355B2 (en) 2002-10-17
US5962444A (en) 1999-10-05
PT1082338E (pt) 2006-11-30
DE69932515T2 (de) 2007-08-09
CA2333668C (en) 2008-05-20
DE69932515D1 (de) 2006-09-07
US6015805A (en) 2000-01-18
EP1082338A1 (en) 2001-03-14
EP1082338B1 (en) 2006-07-26
JP2002517405A (ja) 2002-06-18
ATE334139T1 (de) 2006-08-15
US6093707A (en) 2000-07-25
AU4076299A (en) 1999-12-20
JP4545930B2 (ja) 2010-09-15

Similar Documents

Publication Publication Date Title
DK1082338T3 (da) 17-beta-nitro-11-beta-arylsteroider og derivater heraf med hormonale agonist- eller antagonistegenskaber
DK0804252T3 (da) Monoamin-, diamid-, thiol-holdige metalchelateringsmidler
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
TR200103104T2 (tr) Glukortikoid alıcı modülatörleri
BR0308394A (pt) 5-{2-hidróxi-3-[1-(3-trifluormetilfenil)-ciclopropil]-pr oprionilamino}-ftaleto e compostos relacionados com atividade moduladora de receptores de progesterona para uso em controle da fertilidade e terapia de reposição hormonal
MXPA00008738A (es) 20-ceto-1 1b-arilesteroides y sus derivados teniendo propiedades agonistas o antagonistas hormonales.
CY1109629T1 (el) Συνθεσεις ρυθμιστη υποδοχεα 5ht2c και μεθοδοι χρησης
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
YU7797A (sh) Kombinovana terapija za osteoporozu
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
AR023008A1 (es) 21-hidroxi-6,19-oxidoprogesterona (21oh-6op) para tratar el exceso de glucocorticoides
PL316533A1 (en) Progesterone antagonists used for producing therapeutic agents useful in treating dysfunctional metrorrhagiae
BR0015821A (pt) Derivados de pirimidina
DE60018213D1 (de) Substituierte aminoalkylamid-derivate als antagonisten des follikel-stimulierenden hormons
NZ513096A (en) Compositions for treating inflammatory response
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
WO2002072106A3 (en) Combined method for treating hormono-dependent disorders with exemestane
ATE333462T1 (de) 17 beta-amino und hydroxylamino-11 beta- arylsteroide und deren derivate mit hormonalen agonist- oder antagonisteigenschaften
MXPA02012574A (es) Uso novedoso de los antagonistas ii de angiotensina.
DE60006948T2 (de) Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten
CL2003001545A1 (es) Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei
YU77302A (sh) 8beta-hidrokarbil-supstituisani estratrieni kao selektivno delotvorni estrogeni
YU30103A (sh) Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti